NCT00820560

Open-Label Study to Assess the Safety/Tolerability in Patients With Solid Tumors

A Phase I, Open-Label, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of INCB007839 Following Multiple Oral Doses in Patients With Solid Tumors

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 41 (actual)
• Sponsor: Incyte Corporation · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To establish the maximum tolerated dose (MTD) of INCB007839 given as multiple doses for 28 days and to determine if a higher MTD can be established when INCB007839 is administered in combination with prophylactic anticoagulation and with a 2 and a half day (5 doses) treatment interruption every two weeks.

Conditions

• Solid Tumors and Hematologic Malignancy

Interventions

Type	Name	Description
DRUG	INCB007839	INCB007839 100 or 200 mg/dose as IR capsules

Timeline

• Start date: 2005-01-01
• Primary completion: 2009-01-01
• Completion: 2009-01-01
• First posted: 2009-01-12
• Last updated: 2018-01-17

Locations

4 sites across 1 country: United States